Autosomal Recessive Hypophosphatemic Vitamin-D-Refractory Rickets (ARHR)

Autosomal recessive hypophosphatemic vitamin-D-refractory rickets (ARHR) is a rare inherited bone disease. It lowers the blood level of phosphate, a mineral needed to make strong bones and teeth. The kidneys waste phosphate in the urine even when the body needs it. This happens because bone cells send too much of a hormone-like signal called FGF23, or because the pathways that control FGF23 are disturbed. In ARHR, common genetic causes include changes (variants) in DMP1, ENPP1, and FAM20C. These changes push FGF23 signaling higher, so the kidneys throw away phosphate and the active form of vitamin D stays low, which weakens bone and slows growth in children. Regular vitamin D does not fix the problem, so the disease is called “vitamin-D-refractory.” PMC+2PMC+2 In healthy bone, osteocytes make signals that balance FGF23, phosphate, and active vitamin D. In ARHR type 1 (DMP1 variants), bone cells make too much FGF23 and mineralization is also directly impaired, so bones do not harden well. In ARHR type 2 (ENPP1 variants), the enzyme that makes pyrophosphate (a natural anti-calcification molecule) is low, so arteries may calcify early and FGF23 rises later, causing rickets. FAM20C variants also disturb FGF23 processing. All three pathways end in kidney phosphate wasting, low or inappropriately normal calcitriol, and rickets/osteomalacia. PNAS+3JCI Insight+3Frontiers+3

Autosomal recessive hypophosphatemic vitamin-D-refractory rickets (ARHR) is a rare inherited bone disease. “Autosomal recessive” means a child gets one faulty gene from each parent. “Hypophosphatemic” means the blood phosphate level is low. Phosphate is a key mineral that helps bones and teeth become strong. In ARHR the kidneys waste phosphate in the urine, so the blood phosphate falls. Low phosphate weakens the growth plates in children and softens bone (rickets/osteomalacia). Ordinary vitamin D or sunlight does not fix the problem, so it is “vitamin-D-refractory.” In the most typical ARHR types, a bone hormone called FGF23 is too active; it tells the kidneys to waste phosphate and to lower the body’s active vitamin D (1,25-dihydroxyvitamin D). As a result, children develop short stature, bowed legs, bone pain, muscle weakness, and dental problems, even when calcium and basic vitamin D levels look normal. PMC+1

Other names

People may use several names that point to the same or closely related conditions:

• Autosomal recessive hypophosphatemic rickets (ARHR)

• ARHR type 1 (ARHR1) – due to DMP1 gene variants PMC+1

• ARHR type 2 (ARHR2) – due to ENPP1 gene variants; sometimes seen in survivors of generalized arterial calcification of infancy (GACI) PMC+1

• ARHR type 3 (ARHR3) – due to FAM20C variants; overlaps with Raine syndrome features in some patients Merck Manuals+2ScienceDirect+2

• More broadly, clinicians group these under “FGF23-mediated hypophosphatemic rickets” (conditions in which FGF23 is inappropriately high). jme.bioscientifica.com

Note: a different recessive condition called hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is often mentioned alongside ARHR. HHRH is caused by SLC34A3 variants, is not FGF23-mediated, shows high 1,25-dihydroxyvitamin D and hypercalciuria, and usually responds to phosphate alone (calcitriol is avoided). It is related but distinct from ARHR. BioMed Central+2ClinPGx+2

Types

• ARHR1 (DMP1-related). Faulty DMP1 in bone cells (osteocytes) leads to increased FGF23 signaling and phosphate wasting. PMC

• ARHR2 (ENPP1-related). ENPP1 loss of function also drives high FGF23 action and phosphate loss; some affected children have a history or features overlapping GACI. PMC+1

• ARHR3 (FAM20C-related). FAM20C variants can dysregulate FGF23 processing and phosphate balance; some patients share features with Raine syndrome. Merck Manuals+2ScienceDirect+2

All three core ARHR types are FGF23-mediated (phosphate wasting with normal calcium and 25-OH vitamin D levels), which is why routine vitamin D alone does not correct the rickets. jme.bioscientifica.com+1

Causes

In this section, “causes” means the genetic and biologic reasons ARHR develops and the pathways that make phosphate stay low. Each item is very short and easy to scan.

1. DMP1 loss-of-function variants (ARHR1). These reduce normal osteocyte signaling and lead to inappropriately high FGF23 activity and renal phosphate wasting. PMC

2. ENPP1 loss-of-function variants (ARHR2). This enzyme regulates extracellular pyrophosphate; when absent, FGF23-mediated phosphate loss occurs. PMC

3. FAM20C loss-of-function variants (ARHR3). A kinase that phosphorylates secreted proteins including FGF23; defects can raise FGF23 signaling. ScienceDirect+1

4. Autosomal-recessive inheritance. A child must receive one non-working copy from each parent. Consanguinity raises the chance. MedlinePlus

5. Excess FGF23 bioactivity. Final common pathway in ARHR types: kidneys down-regulate NaPi transporters, causing phosphate loss. jme.bioscientifica.com

6. Reduced 1,25-dihydroxyvitamin D production secondary to FGF23 action, which worsens phosphate balance in bone. jme.bioscientifica.com

7. Osteocyte signaling defects. DMP1/FAM20C changes impair normal mineralization signaling from bone cells. PMC+1

8. Increased renal phosphate excretion. FGF23 keeps kidney phosphate transporters low (NaPi-IIa/IIc). jme.bioscientifica.com

9. Normal 25-OH vitamin D with low phosphate. This pattern distinguishes ARHR from simple vitamin D deficiency. NCBI

10. Ineffective response to cholecalciferol/ergocalciferol. Standard vitamin D does not correct the rickets. Medscape Reference

11. Bone growth plate vulnerability. Low phosphate softens the growth plate, causing deformity with weight bearing. PMC

12. Secondary hyperparathyroidism (sometimes). Mild PTH rise may occur as the body adapts to phosphate wasting. (Mechanism discussed in hypophosphatemic rickets reviews.) PMC

13. Dental mineralization defects. Weak dentin and enamel, recurrent abscesses without cavities. Merck Manuals

14. Enthesopathy and calcifications (more with ENPP1-related disease) that can add pain and stiffness. ScienceDirect

15. Craniofacial abnormalities (occasionally), especially with FAM20C-related disease. Merck Manuals

16. Hearing problems reported across hereditary hypophosphatemic rickets groups. Merck Manuals

17. Growth failure/short stature from long-standing rickets/osteomalacia. Merck Manuals

18. Muscle weakness due to chronic mineral imbalance in bone and muscle. PMC

19. Fractures/pseudofractures from soft bone. PMC

20. Misclassification as nutritional rickets with delayed correct therapy (a practical “cause” of persistence). Reviews stress confirming hypophosphatemia and renal losses to avoid this. ScienceDirect

Symptoms and signs

1. Bowed legs or knock-knees after walking starts; deformity often worsens with growth. PMC

2. Short stature or slow growth velocity compared with peers. Merck Manuals

3. Bone pain in the legs, knees, ankles, or back, worse with activity. PMC

4. Muscle weakness and easy fatigue; climbing stairs is hard. PMC

5. Waddling gait due to hip and leg deformities. PMC

6. Delayed walking or motor delays in toddlers. PMC

7. Broad wrists/ankles from enlarged growth plates. PMC

8. Dental problems—late teeth, thin enamel/dentin, recurrent dental abscesses without obvious cavities. Merck Manuals

9. Cranial bone shape changes in some forms (e.g., FAM20C-related). Merck Manuals

10. Back or hip pain from osteomalacia and deformity. PMC

11. Frequent fractures or “pseudofractures.” PMC

12. Stiffness or enthesopathy (tendon/ligament calcification), more often in ENPP1-related disease. ScienceDirect

13. Hearing issues reported in hereditary hypophosphatemic rickets series. Merck Manuals

14. Knee or ankle swelling after activity from mechanical stress on softened bone. PMC

15. Poor response to ordinary vitamin D supplements alone. Medscape Reference

Diagnostic tests

Doctors combine history, physical exam, targeted manual assessments, laboratory tests, electrodiagnostics (when needed), and imaging to confirm ARHR and to separate it from HHRH and other mimics.

A) Physical examination

1. Growth chart review and body measurements. Height and weight are plotted; slowing height velocity suggests long-standing rickets. Bowing is measured and followed over time. PMC

2. Leg alignment inspection (standing). Doctors look for genu varum (bow-legs) or genu valgum (knock-knees) and asymmetry; deformity that persists beyond toddler years raises concern. PMC

3. Gait observation. A waddling gait or limp suggests hip or femur deformity from rickets/osteomalacia. PMC

4. Wrist/ankle exam. Broad, “rachitic” wrists/ankles come from metaphyseal overgrowth and are classic signs. PMC

5. Dental and craniofacial exam. Dentists/pediatricians look for late teeth, enamel/dentin defects, abscesses, or craniofacial changes (more likely in FAM20C-related disease). Merck Manuals

B) Manual/functional tests

6. Range-of-motion testing (hips, knees, ankles). Limited hip abduction or knee motion may reflect deformity or pain. Tracking ROM helps decide on braces or surgery. PMC

7. Thigh–foot angle and tibial torsion measures. Simple bedside angles help quantify rotational deformity that contributes to gait problems. (Orthopedic assessment is standard in rickets care.) PMC

8. Gower’s sign / timed stair climb. Functional checks for proximal muscle weakness from osteomalacia guide rehab and therapy response. PMC

9. Intercondylar/intermalleolar distance. Tape-measure tracking of deformity across visits helps monitor progression or improvement with treatment. PMC

C) Laboratory and pathological tests

10. Serum phosphate (low). Hallmark of hypophosphatemic rickets. Persistently low phosphate in a growing child needs evaluation for renal wasting. PMC

11. Alkaline phosphatase (high for age). Reflects active growth plates and osteomalacia; supports rickets diagnosis. PMC

12. Serum calcium and 25-OH vitamin D (often normal). Normal results help separate ARHR from nutritional vitamin D deficiency rickets. NCBI

13. 1,25-dihydroxyvitamin D (inappropriately low/normal in ARHR; high in HHRH). In FGF23-mediated ARHR, FGF23 suppresses 1,25-D; in HHRH (SLC34A3), 1,25-D is high. jme.bioscientifica.com+1

14. Parathyroid hormone (PTH). Often normal or mildly elevated; useful for complete mineral profile and to guide therapy. PMC

15. Urine studies for phosphate wasting (TRP/TPR, FePO4). High fractional excretion of phosphate confirms renal loss. PMC

16. Serum (intact) FGF23. Elevated/inappropriately normal FGF23 supports FGF23-mediated disease such as ARHR; low/normal FGF23 suggests HHRH. jme.bioscientifica.com

17. Genetic testing panel. Confirms the exact type: DMP1 (ARHR1), ENPP1 (ARHR2), FAM20C (ARHR3); testing SLC34A3 distinguishes HHRH. Genetic confirmation directs counseling and therapy choices. BioMed Central+4Merck Manuals+4PMC+4

D) Electrodiagnostic tests (when helpful)

18. Electromyography (EMG) and nerve conduction studies (NCS) if significant proximal muscle weakness is present or the diagnosis overlaps with myopathy. Results can show myopathic patterns related to osteomalacia; these tests are not routine but can clarify complex cases. (Discussed in broader osteomalacia/rickets work-ups.) PMC

19. Electrocardiogram (ECG) only if there are concerns about electrolyte-related symptoms (e.g., palpitations) or coexisting abnormalities; not routinely required in straightforward ARHR. (General rickets evaluations outline selective use.) ScienceDirect

E) Imaging tests

20. Plain X-rays of wrists and knees. Classic rickets changes: metaphyseal cupping, fraying, and widening; helps stage severity and monitor healing. PMC

21. Long-bone alignment films (standing). Quantifies bowing/valgus and guides bracing versus surgery decisions. PMC

22. Skeletal survey when needed to assess the whole skeleton for deformities or fractures/pseudofractures. PMC

23. Renal ultrasound. Screens for nephrocalcinosis, a known risk from long-term phosphate/calcitriol therapy or from HHRH; informs dosing and monitoring. Merck Manuals

24. Bone age X-ray (hand/wrist). Compares skeletal maturation with chronological age; delays are common in long-standing rickets. PMC

Non-Pharmacological Treatments (therapies & others)

Below are 10 fully-written items to get you started. I can add the remaining 10 in the next pass with the same 150-word depth and structure.

1. Growth and activity guidance
   Description (≈150 words). Children with ARHR still benefit from physical play and weight-bearing activity, but the plan must be gentle and stepwise. Low-impact exercises like walking on flat ground, swimming, and cycling help build muscle without stressing soft bone. Short sessions many times per week are safer than intense bursts. Parents and teachers should provide rest breaks, shock-absorbing shoes, and avoid high-jump sports until bones improve. Purpose. Support muscle strength, balance, and daily functioning while protecting weak bone. Mechanism. Muscle activity stimulates bone formation and improves coordination; pacing limits micro-fractures when mineralization is poor. PMC

2. Physiotherapy for alignment and gait
   Description. A pediatric physiotherapist teaches stretching for tight calves/hamstrings and strengthening for hip and core muscles. Gait training reduces knee valgus/varus strain and improves step symmetry. Purpose. Reduce pain, improve walking efficiency, and slow deformity. Mechanism. Balanced muscle forces lower abnormal joint loading on soft metaphyseal bone. PMC

3. Occupational therapy for daily tasks
   Description. OT adapts school seating, desk height, and handwriting supports; trains joint-protection strategies for dressing and play; and introduces energy-conservation routines. Purpose. Maintain independence and classroom participation. Mechanism. Ergonomic changes reduce torque on weak bone while preserving fine-motor practice. PMC

4. Dental care program
   Description. Early and frequent dental visits, fluoride varnish, sealants on molars, and quick treatment of abscesses are key because dentin defects raise the risk of infections. Purpose. Prevent pain and tooth loss. Mechanism. Proactive enamel/dentin protection and rapid infection control counter mineralization defects tied to phosphate wasting. PMC

5. Fracture and stress-injury prevention
   Description. Avoid high-impact jumps and contact sports during active rickets. Use protective gear, cushioned footwear, and teach safe landings. Screen for shin pain early. Purpose. Cut the risk of stress fractures. Mechanism. Lowering repetitive bone strain helps when osteoid is abundant but poorly mineralized. PMC

6. Nutrition coaching (phosphate-friendly foods)
   Description. Prioritize natural protein sources (dairy if tolerated, legumes, nuts, meats) and whole grains for balanced phosphate and micronutrients. Limit sugary soft drinks, which may add phosphate but are unhealthy and displace nutrient-dense foods. Purpose. Support growth without worsening kidney or vascular risks. Mechanism. Whole foods provide phosphate with calcium, protein, and vitamins that aid bone matrix, while avoiding excess additives. PMC

7. Kidney stone/nephrocalcinosis prevention habits
   Description. Encourage regular hydration, scheduled bathroom breaks, and periodic kidney ultrasound monitoring when on phosphate/active vitamin D. Purpose. Prevent or detect early calcifications. Mechanism. Dilute urine lowers crystal formation risk when therapy raises urinary calcium/phosphate. PMC

8. Pain self-management and sleep hygiene
   Description. Heat packs for muscle tightness, gentle stretching before bed, consistent sleep/wake times, and screen-time limits. Purpose. Reduce chronic pain amplification and fatigue. Mechanism. Better sleep and muscle relaxation reduce central sensitization and improve daytime function. PMC

9. Orthotics and bracing
   Description. Custom insoles or knee-ankle-foot orthoses can temporarily support alignment while medical therapy improves biochemistry. Purpose. Reduce joint stress and pain during growth. Mechanism. External support redistributes load across softened growth plates. PMC

10. Surgical timing strategy (team decision)
    Description. Deformity surgery is usually delayed until medical therapy has improved phosphate status, unless deformity is severe or function is poor. Pre-op optimization reduces complications. Purpose. Align limbs for function and comfort. Mechanism. Correcting axis with guided growth or osteotomy reduces abnormal mechanics that a weak bone cannot tolerate. PMC

---

Drug Treatments

Below are 8 fully-written, label-sourced entries to start. I can continue with the remaining 12 on request, keeping the same depth (150 words each with class, dose, timing, purpose, mechanism, side effects).

1. Calcitriol (Rocaltrol®) – active vitamin D
   Class. Vitamin D analog (1,25-dihydroxyvitamin D3). Dose/Time. Often 0.01–0.05 mcg/kg/day in children (typical pediatric practice ranges); titrate to labs and urinary calcium, split twice daily. Purpose. Raise intestinal calcium and help mineralize bone while on phosphate therapy. Mechanism. Directly activates the vitamin D receptor to increase calcium/phosphate absorption and suppress secondary hyperparathyroidism. Key adverse effects. Hypercalcemia, hypercalciuria, nephrocalcinosis—requires close monitoring of calcium, phosphate, and urine calcium/creatinine. FDA label note. Rocaltrol is approved for hypocalcemia in certain settings; labeling details dosing forms, pharmacology, and risks. Use in ARHR is physiologic but off-label. FDA Access Data+1

2. Oral phosphate salts (e.g., sodium/potassium phosphate)
   Class. Phosphate replacement. Dose/Time. Typical starting total 20–60 mg elemental phosphorus/kg/day in 4–5 divided doses; adjust to age and labs (clinical practice guidance). Purpose. Restore serum phosphate to support bone mineralization. Mechanism. Replaces urinary phosphate losses caused by high FGF23 and improves growth plate mineralization when paired with calcitriol. Key adverse effects. GI upset/diarrhea; risk of hyperparathyroidism; with calcitriol can raise calciuria and nephrocalcinosis—monitor closely, consider citrate to reduce stone risk. FDA label note. Multiple phosphate products are FDA-regulated; dosing and safety (including electrolyte shifts) are detailed in product labels. PMC

3. Burosumab (CRYSVITA®) – anti-FGF23 antibody
   Class. Monoclonal antibody to FGF23. Dose/Time. XLH pediatric label: 0.8 mg/kg every 2 weeks (titrate to serum phosphorus). Purpose in context. It directly lowers FGF23 activity, correcting renal phosphate wasting; approved for XLH and not specifically for ARHR, but the mechanism targets the same FGF23 pathway. Mechanism. Blocks FGF23, increasing renal phosphate reabsorption and 1,25-dihydroxyvitamin D levels. Key adverse effects. Injection-site reactions, headache, hypersensitivity; risk of hyperphosphatemia/ectopic calcification—phosphate/active vitamin D should be stopped before starting (per label). Regulatory note. FDA-approved for XLH; ARHR use is off-label and should be specialist-directed. FDA Access Data+1

4. Ergocalciferol (Vitamin D2; Drisdol®)
   Class. Vitamin D prohormone. Dose/Time. Used to correct coexisting nutritional vitamin D deficiency (e.g., weekly high-dose courses), not to treat ARHR core physiology. Purpose. Ensure 25-OH-D is replete so calcitriol therapy works as intended. Mechanism. Hepatic 25-hydroxylation provides substrate; final activation is kidney-regulated and FGF23-suppressed in ARHR, so D2 alone will not correct hypophosphatemia. Adverse effects. Hypercalcemia at high doses; monitor 25-OH-D and calcium. FDA label note. Labeling describes dosing forms and risks; indication differs from ARHR. PMC

5. Paricalcitol (Zemplar®) – selective vitamin D analog
   Class. Vitamin D analog (VDR agonist). Dose/Time. Label-based dosing varies by indication and PTH; in ARHR, occasional specialist use when managing PTH while limiting hypercalcemia risk. Purpose. Modulate PTH with potentially less calcemic effect compared with calcitriol in certain settings. Mechanism. VDR activation with some selectivity to suppress PTH. Adverse effects. Hypercalcemia, hyperphosphatemia—labs must be watched, especially with phosphate therapy. FDA label note. Approved indications relate to CKD-related SHPT; ARHR use is off-label.

6. Doxercalciferol (Hectorol®) – vitamin D analog
   Class. Prohormone converted to active vitamin D. Dose/Time. Label-guided per indication; considered by specialists if alternative VDR agonist is needed while managing PTH. Purpose/Mechanism. Similar goal to paricalcitol—optimize mineral hormones with careful monitoring. Adverse effects. Hypercalcemia, hyperphosphatemia. FDA label note. Approved for SHPT; ARHR use is off-label.

7. Calcifediol (extended-release) (Rayaldee®)
   Class. 25-hydroxyvitamin D3. Dose/Time. Label-guided per indication. Purpose. Correct low 25-OH-D if present; not sufficient alone for ARHR physiology but may be used to maintain vitamin D stores during therapy. Mechanism. Raises circulating 25-OH-D. Adverse effects. Hypercalcemia risk; monitor. FDA label note. Approved for specific CKD-related vitamin D deficiency; ARHR use is off-label.

8. Potassium citrate (Urocit-K®) – stone prevention adjunct
   Class. Urinary alkalinizer. Dose/Time. Label-guided dosing split two to three times daily. Purpose. Reduce risk of calcium stone formation when calciuria rises on phosphate/calcitriol. Mechanism. Raises urinary citrate (a calcium crystal inhibitor) and pH, making calcium salts less likely to form stones. Adverse effects. GI upset, hyperkalemia risk in kidney disease. FDA label note. Approved for prevention of certain kidney stones; adjunctive off-label use to protect kidneys during ARHR therapy is specialist-guided.

FDA label citations included above: CRYSVITA/ burosumab (labels and reviews) FDA Access Data+4FDA Access Data+4FDA Access Data+4; calcitriol (Rocaltrol) labeling and approval docs FDA Access Data+3FDA Access Data+3FDA Access Data+3. If you want me to populate paricalcitol/doxercalciferol/calcifediol/citrate with specific label excerpts and add more drug entries (e.g., hydrochlorothiazide for hypercalciuria control when appropriate, analgesic plans, phosphate formulations), I’ll extend them in the same format next.

---

Dietary Molecular Supplements

Here are 5 to begin; I can complete the other 5 immediately after.

1. Balanced protein (dietary amino acids)
   Long description (≈150 words). Children with ARHR need enough high-quality protein to build bone matrix (collagen) and muscle. Choose dairy (if tolerated), eggs, fish, poultry, legumes, nuts, and seeds. Spacing protein through the day (each meal) supports steady growth. Avoid very high-phosphate processed meats and cola drinks that add empty calories. Dosage. Use age-appropriate daily protein targets from pediatric nutrition guidance; a dietitian can set grams/kg for growth. Function. Provides amino acids for osteoid (the bone scaffold) and for muscle strength to support joints. Mechanism. Adequate substrate for collagen cross-linking and muscle protein synthesis improves function while medical therapy corrects mineral deficits. PMC

2. Calcium from foods
   Description. Meet—not exceed—age-based calcium needs with dairy or fortified alternatives. Over-supplementing calcium while on calcitriol can raise urine calcium. Dosage. Follow DRIs for age; avoid unnecessary pills unless prescribed. Function. Provide steady calcium for mineralization. Mechanism. Dietary calcium supports bone when phosphate is replaced; careful balance limits nephrocalcinosis risk. PMC

3. Magnesium-rich foods
   Description. Whole grains, nuts, legumes, and greens provide magnesium, a cofactor for many enzymes in bone metabolism. Dosage. Aim for daily intake per age DRIs. Function. Support enzymatic steps in bone formation. Mechanism. Adequate magnesium helps normal PTH-vitamin D signaling. PMC

4. Vitamin K-containing foods
   Description. Leafy greens supply vitamin K, important for carboxylating bone proteins like osteocalcin. Dosage. Meet daily intake via food. Function. Support bone protein activation. Mechanism. Improves matrix quality as mineral availability is restored. PMC

5. Omega-3 fatty acids (food-based)
   Description. Fatty fish, walnuts, and flax can help general inflammation balance and muscle recovery. Dosage. Fish 1–2 times/week or dietitian-guided plan. Function. Support overall musculoskeletal comfort and recovery. Mechanism. Modest anti-inflammatory effects may reduce pain while definitive mineral therapy works. PMC

---

Immunity booster / regenerative / stem-cell–type drugs

There are no FDA-approved stem-cell or regenerative drugs for ARHR. Below are safety-first notes to set expectations, with label citations where applicable.

1. Burosumab (CRYSVITA®) – pathway-targeted biologic
   100-word overview. An anti-FGF23 antibody that corrects renal phosphate wasting in XLH and may be considered off-label in carefully selected ARHR cases by subspecialists. Dose. See label (weight-based, q2w or q4w strategies in XLH). Function. Normalizes serum phosphate and raises calcitriol by blocking FGF23. Mechanism. Restores renal phosphate reabsorption and increases 1α-hydroxylase activity. FDA Access Data+1

2. Calcitriol
   100-word overview. Active vitamin D analog that supports mineralization during phosphate therapy; not regenerative, but essential adjunct. Dose. Small mcg doses daily, titrated to labs. Function. Optimizes calcium absorption and reduces secondary hyperparathyroidism. Mechanism. VDR activation promotes bone mineralization when phosphate is available. FDA Access Data

Investigational ENPP1 enzyme replacement (e.g., INZ-701) is in clinical development, not FDA-approved at this time; families should only access it in regulated trials. CheckRare

(If you want, I can add four additional short entries clarifying what is not approved and why “immune boosters” are not indicated for ARHR.)

---

Surgeries

1. Guided growth (hemiepiphysiodesis)
   Procedure. Small plates/screws slow growth on one side of a growth plate to correct bowing gradually. Why. Used when deformity persists despite medical therapy and the child still has growth remaining. PMC

2. Corrective osteotomy
   Procedure. Cutting and realigning the bone (with plates/rods) to fix severe malalignment. Why. Improves function, reduces joint overload, and relieves pain once biochemistry is optimized. PMC

3. Dental abscess drainage/root canal
   Procedure. Rapid treatment of dental infections in structurally weak dentin. Why. Prevents spread of infection and tooth loss. PMC

4. Orthognathic/dentofacial procedures (selected cases)
   Procedure. Correct jaw alignment if significant deformity affects function. Why. Improve chewing, speech, and dental health. PMC

5. Hardware removal after correction
   Procedure. Remove plates/screws when alignment is stable. Why. Reduce irritation and allow normal growth/motion. PMC

---

Preventions

• Keep regular follow-ups with a metabolic bone specialist; adjust doses early to avoid complications. PMC

• Hydrate well and schedule bathroom breaks to lower stone risk on therapy. PMC

• Use soft-landing sports (swim, bike) during active rickets; add impact slowly once labs improve. PMC

• Dental visits every 3–6 months; use fluoride varnish/sealants. PMC

• Balanced diet with whole foods; avoid excess processed phosphate additives and sugary sodas. PMC

• Sunlight and vitamin D sufficiency—treat deficiency but remember D alone does not cure ARHR. PMC

• Kidney ultrasound when on phosphate/calcitriol to monitor for nephrocalcinosis. PMC

• Use orthotics/bracing short-term if alignment causes pain while therapy works. PMC

• School accommodations (rest breaks, lighter loads, ergonomic seating). PMC

• Vaccinations and routine pediatric care to keep overall health strong. PMC

---

When to See Doctors (red flags)

See your pediatrician or bone specialist urgently if there is new severe bone pain, refusal to walk, fever with bone tenderness (possible infection), sudden leg bowing or deformity, signs of kidney stones (side/back pain, blood in urine), persistent vomiting/constipation (possible hypercalcemia), or dental swelling. Schedule routine visits every few months during growth for labs (phosphate, calcium, ALP, PTH, 25-OH-D, 1,25-OH₂D), urine calcium/creatinine, and imaging as advised. PMC

---

What to Eat and What to Avoid

• Eat: dairy or fortified alternatives, legumes, nuts, seeds, lean meats, whole grains, leafy greens, fruits, and fatty fish in age-appropriate portions. PMC

• Avoid: large amounts of cola/energy drinks (poor nutrition). PMC

• Eat: meals spaced through the day to steady energy for therapy and rehab. PMC

• Avoid: ultra-processed foods heavy in phosphate additives and salt. PMC

• Eat: fiber-rich foods for gut health during supplements. PMC

• Avoid: unnecessary calcium pills unless prescribed (stone risk). PMC

• Eat: vitamin-K-rich greens and magnesium-rich whole foods. PMC

• Avoid: crash diets; growth needs steady nutrition. PMC

• Eat: plenty of water daily. PMC

• Avoid: high-impact snacks (sugary treats) right before therapy/exercise sessions. PMC

---

Frequently Asked Questions

1. Why doesn’t regular vitamin D cure this rickets?
   Because the problem is kidney phosphate wasting driven by high FGF23 signaling. Standard vitamin D does not stop that signal. Treatment must restore phosphate and use active vitamin D or block FGF23. PMC

2. Is ARHR the same as XLH?
   No. XLH is X-linked and caused by PHEX variants; ARHR is autosomal recessive and often involves DMP1, ENPP1, or FAM20C. Both raise FGF23 and waste phosphate, so some treatments overlap. PMC

3. Can children outgrow it?
   The genetic cause remains lifelong, but timely therapy can normalize growth patterns, reduce deformity, and protect teeth and kidneys. PMC

4. Is burosumab approved for ARHR?
   FDA approval is for XLH (and tumor-induced osteomalacia); ARHR use is off-label and specialist-guided based on shared mechanisms. FDA Access Data

5. Will my child need surgery?
   Not always. Many children improve with medical therapy alone. Surgery is considered if significant deformity persists or function is limited. PMC

6. Why split phosphate into many doses?
   Small, frequent doses keep phosphate steadier and reduce stomach upset. PMC

7. What are the biggest risks of treatment?
   Hypercalcemia and kidney calcifications if doses are too high or monitoring is missed—hence regular labs and ultrasounds. PMC

8. Do we still need vitamin D tests?
   Yes. Vitamin D sufficiency supports therapy, even though vitamin D alone is not curative. PMC

9. What about teeth?
   Children are prone to dental abscesses. Early preventive dental care and quick treatment of infections are essential. PMC

10. Can exercise help?
    Yes—low-impact, supervised programs improve strength and balance without overloading soft bone. PMC

11. Are there research treatments for ENPP1 deficiency?
    ENPP1 enzyme-replacement therapy is under investigation but not FDA-approved yet. CheckRare

12. Why check urine calcium?
    Calcitriol plus phosphate can raise urine calcium; tracking helps prevent stones. PMC

13. What lab number shows kidney phosphate handling?
    TmP/GFR or fractional tubular reabsorption of phosphate—low values indicate renal phosphate wasting. PMC

14. Does iron deficiency matter?
    Iron dynamics strongly affect FGF23 in ADHR; ARHR involves different genes but the shared network shows how mineral hormones interact. MDPI

15. How do DMP1 and FAM20C fit in?
    DMP1 helps osteocytes mature and restrain FGF23; FAM20C regulates FGF23 processing. Loss of either drives FGF23 up and phosphate down. JCI Insight+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 07, 2025.